News

Dr. Bishoy Faltas, an assistant professor of medicine at Weill Cornell Medicine and an oncologist at New York Presbyterian/Weill Cornell Medical Center, has been awarded a Career Development Award from the Department of Defense to investigate the biology of a family of proteins thought to drive resistance to chemotherapy in the advanced stages of bladder cancer.

Two Weill Cornell Medicine investigators have received 2017 Clinical Scientist Development Awards from the Doris Duke Charitable Foundation to support their ongoing research projects. 

Dr. Hugh Hemmings, Jr. has been appointed senior associate dean for research and Dr. Todd Evans has been appointed associate dean for research at Weill Cornell Medicine.

Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

By studying the effects of immune cells that surround blood vessels in the brain, Weill Cornell Medicine researchers have discovered a new pathway involving these cells that may contribute to the cause of Alzheimer’s disease.

Like many surgeons, Dr. Jason Spector is often faced with the challenge of securely closing the abdominal wall without injuring the intestines.

A deeper understanding of the brain’s connectivity network of neurons and its relationship to the organ’s deep tissue could allow researchers to predict brain spatial patterns and recognize what processes relate to neurological disorders.

Amanda Garfinkel, a third-year medical student at Weill Cornell Medical College, was awarded a one-year fellowship from the Sarnoff Cardiovascular Research Foundation.

An enzyme implicated in autoimmune diseases and viral infections also regulates radiation therapy’s ability to trigger an immune response against cancer.

The first-ever “disease in a Petri dish” platform that models human colon cancer derived from stem cells has been developed by Weill Cornell Medicine investigators, allowing them to identify a targeted drug treatment for a common, inherited form of the disease.

A calcium-dependent molecular mechanism discovered in the brain cells of mice by Weill Cornell Medicine investigators may underlie the impaired social interactions and anxiety found in neuropsychiatric disorders — including schizophrenia and autism.

Dr. Conor Liston, an assistant professor of neuroscience in the Feil Family Brain and Mind Institute and an assistant professor of psychiatry at Weill Cornell Medicine, has been named a Rita Allen Foundation Scholar.

New imaging methods that allow researchers to track the individual protein molecules on the surface of cells have been developed by Weill Cornell Medicine investigators. The results offer unprecedented insight into how cells sense and respond to their environments. 

A technique developed by Weill Cornell Medicine and NewYork-Presbyterian investigators can detect cancer cells surviving therapy in the most common form of leukemia in adults more sensitively and precisely than traditional microscopic observation.

Atrial fibrillation is a condition that affects as many as 6.1 million Americans and is characterized by an irregular, often rapid heart rate caused by a misfiring of electrical impulses. 

NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.

A new study suggests that ketamine doesn’t lower levels of pain or reduce the need for pain-killing opioid drugs in the days after an operation.

Ankur Singh, assistant professor in the Sibley School of Mechanical and Aerospace Engineering and the Meinig School of Biomedical Engineering, has won a three-year, $555,000 grant from the U.S. Department of Defense (DoD) through its Peer Reviewed Cancer Research Program (PRCRP), to further his study of diffuse large B-cell lymphoma. Singh’s mentor is Dr. Ari Melnick at Weill Cornell Medicine.

Neel Madhukar and Katie Gayvert are driven by similar experiences of close family members developing tumors. Now close friends, their award winning, co-authored studies focus on applying machine learning techniques to predict drug efficacy to maximize benefits for patients.